With semaglutide patent ending, Indian pharma firms are set to launch lower-cost versions, prompting hospitals and clinics to expand obesity services ahead of a surge in demand.
Semaglutide, active ingredient in popular weight-loss drugs, including Ozempic and Wegovy, belongs to the class of medications known as GLP-1 receptor agonists.
Interest in GLP-1s for addiction has grown in the past decade, as some people prescribed them for diabetes or weight loss noticed they were drinking less alcohol or smoking less.
The panel discussing Ambrish Mithal and Shivam Vij’s book on obesity and weight loss drugs included Minister of State Jitendra Singh, actor Sharmila Tagore, and HT Media chairperson Shobhana Bhartia.
Pharma firms are pouncing on opportunity as patents on world’s second-bestselling drug, which goes by brand names Ozempic and Wegovy, are expiring in nearly 100 nations.
The one thing that keeps the relentless beauty of trans people alive is their community. But for lawmakers, kinship is ‘deception’, ‘allurement’, and ‘undue influence’.
Aluminum prices, already rising before the conflict, have gained further as traders and buyers focus on the potential for tighter markets and shrinking global inventories.
It’s easy to understand why the government can’t speak the hard truth. When this war ends, as all wars do, India’s interests will lie with both the winner and the loser.
COMMENTS